These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). Hsu A, Yao HM, Gupta S, Modi NB. J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267 [Abstract] [Full Text] [Related]
25. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease. Greig SL, McKeage K. CNS Drugs; 2016 Jan; 30(1):79-90. PubMed ID: 26692288 [Abstract] [Full Text] [Related]
26. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Deleu D, Jacques M, Michotte Y, Ebinger G. Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654 [Abstract] [Full Text] [Related]
27. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study]. Chaná P, Fierro A, Reyes-Parada M, Sáez-Briones P. Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590 [Abstract] [Full Text] [Related]